New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
09:12 EDTRENN, PSUN, OWW, EXAS, KBH, RBCN, HZNP, ORCLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: KB Home (KBH), up 7%...Pacific Sunwear (PSUN), up 7%. ALSO HIGHER: Horizon Pharma (HZNP), up 23% after deal to acquire Ireland's Vidara Therapeutics through reverse merger... Exact Sciences (EXAS), up 6.5% after a clinical trial of its Cologuard test, which it co-developed with the Mayo Clinic, showed "unprecedented" rates of precancer and cancer detection by a noninvasive test... DOWN AFTER EARNINGS: Oracle (ORCL), down 3.3%... Renren (RENN), down 7%. ALSO LOWER: Orbitz (OWW), down 5.4% after Goldman downgraded shares to Sell from Neutral... Rubicon (RBCN), down 6% after 2.5M share spot secondary offering priced at $13.00.
News For OWW;ORCL;KBH;PSUN;HZNP;EXAS;RENN;RBCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 21, 2015
09:13 EDTEXASExact Sciences 7M share Spot Secondary priced at $25.50
Subscribe for More Information
07:15 EDTORCLOracle management to meet with Deutsche Bank
Subscribe for More Information
07:02 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
Horizon Pharma (HZNP) announced that it has increased the value of its all-stock acquisition proposal to $33.00 per share from $29.25 per share, contingent on Depomed entering into good faith discussions regarding a transaction. The increased offer represents a 60% premium to the closing price of Depomed on July 6, the day prior to when Horizon's initial proposal was made public.
07:01 EDTHZNPHorizon Pharma increases offer for Depomed to $33.00 per share
July 20, 2015
19:02 EDTEXASOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTEXASExact Sciences files to sell 7M shares of common stock
The Company intends to use the net proceeds of this offering to fund expansion of Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes. Jefferies LLC and Robert W. Baird & Co. Incorporated are acting as the underwriters for the offering.
10:33 EDTHZNPDepomed suitor Horizon Pharma advances after raising outlook
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says 'here to stick it out' regarding Depomed deal
Subscribe for More Information
09:50 EDTHZNPHorizon Pharma CEO says Depomed proposal 'shareholder friendly'
Subscribe for More Information
09:22 EDTEXAS, HZNPOn The Fly: Pre-market Movers
Subscribe for More Information
07:16 EDTHZNPHorizon Pharma up 5.2% after reporting preliminary Q2 revenue, raises FY15 view
Subscribe for More Information
07:07 EDTORCLOracle management to meet with Deutsche Bank
Meetings to be held in Montreal/Toronto on July 20 hosted by Deutsche Bank.
07:07 EDTOWWOrbitz rewards program exceeds 4M members
Subscribe for More Information
07:05 EDTHZNPHorizon Pharma raises FY15 revenue guidance to $660M-$680M from $590M-$610M
Consensus $611.6M. Raises FY15 adjusted EBITDA guidance to $265M-$280M from $235M-$250M.
07:04 EDTHZNPHorizon Pharma sees Q2 revenue $170M-$172M, consensus $138.26M
05:32 EDTEXASExact Sciences reports Q2 EPS (44c), consensus (45c)
Reports Q2 revenue $8.1M, consensus $7.96M.
July 16, 2015
18:48 EDTORCLOracle drops largest copyright damages theory against Rimini Street
Subscribe for More Information
11:39 EDTORCLOracle management to meet with Evercore ISI
Subscribe for More Information
10:04 EDTHZNPHigh option volume stocks
High option volume stocks: TWX PMCS SHW ASML GRMN GSAT ROVI ALLY LC HZNP
06:25 EDTORCLOracle announces 'disciplined reduction' in overall compensatoin
Oracle announced bonuses to Ellison, Catz and Hurd will be paid out at $0 in FY15, compared to 16% targe tin FY14. Oracle said that no performance-based cash bonuses will be awarded in years where no growth in non-GAAP pre-tax profits is achieved. PSU payouts are based on Oracle revenue growth and operating cash flow growth relative to select peer company performances. In connection with the management transition in 2015, the compensation committee canceled 1.5M equity equivalent shares of Ellison's FY15 equity award. The company announced option awards will be reduced to 5 year terms from 10 year terms in 2016, significantly reducing its value and maintaining long-term vest. Comments taken from slides for July Investor Presentation.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use